Cervicovaginal Immune Activation in Zambian Women With Female Genital Schistosomiasis

Amy S. Sturt1*, Emily L. Webb2, Catriona Patterson3, Comfort R. Phiri4, Tobias Mweene4, Eyrun F. Kjetland5,6, Maina Mudenda7, Joyce Mapani7, Mable M. Mutengo8, James Chipeta9, Govert J. van Dam10, Paul L. A. M. Corstjens11, Helen Ayles1,4, Richard J. Hayes2, Isaiah Hansingo7, Piet Cools12, Lisette van Lieshout10, Helena Helmby3, Grace A. McComsey13, Suzanna C. Francis2 and Amaya L. Bustinduy1

1 Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom, 2 MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom, 3 Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom, 4 Zambart, Lusaka, Zambia, 5 Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, 6 University of KwaZulu-Natal, Discipline of Public Health, Durban, South Africa, 7 Department of Obstetrics and Gynecology, Livingstone Central Hospital, Livingstone, Zambia, 8 Institute of Basic and Biomedical Sciences, Levy Mwanawasa Medical University, Lusaka, Zambia, 9 Department of Pediatrics, University of Zambia, Lusaka, Zambia, 10 Department of Parasitology, Leiden University Medical Center, Leiden, Netherlands, 11 Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands, 12 Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium, 13 University Hospitals Cleveland Medical Center and Case Western Reserve University, Department of Pediatrics and Medicine, Cleveland, OH, United States

HIV-1 infection disproportionately affects women in sub-Saharan Africa, where areas of high HIV-1 prevalence and Schistosoma haematobium endemcity largely overlap. Female genital schistosomiasis (FGS), an inflammatory disease caused by S. haematobium egg deposition in the genital tract, has been associated with prevalent HIV-1 infection. Elevated levels of the chemokines MIP-1\(\alpha\) (CCL-3), MIP-1\(\beta\) (CCL-4), IP-10 (CXCL-10), and IL-8 (CXCL-8) in cervicovaginal lavage (CVL) have been associated with HIV-1 acquisition. We hypothesize that levels of cervicovaginal cytokines may be raised in FGS and could provide a causal mechanism for the association between FGS and HIV-1. In the cross-sectional BILHIV study, specimens were collected from 603 female participants who were aged 18–31 years, sexually active, not pregnant and participated in the HPTN 071 (PopART) HIV-1 prevention trial in Zambia. Participants self-collected urine, and vaginal and cervical swabs, while CVLS were clinically obtained. Microscopy and Schistosoma circulating anodic antigen (CAA) were performed on urine. Genital samples were examined for parasite-specific DNA by PCR. Women with FGS (n=28), defined as a positive Schistosoma PCR from any genital sample were frequency age-matched with 159 FGS negative (defined as negative Schistosoma PCR, urine CAA, urine microscopy, and colposcopy imaging) women. Participants self-collected urine, and vaginal and cervical swabs, while CVLS were clinically obtained. Microscopy and Schistosoma circulating anodic antigen (CAA) were performed on urine. Genital samples were examined for parasite-specific DNA by PCR. Women with FGS (n=28), defined as a positive Schistosoma PCR from any genital sample were frequency age-matched with 159 FGS negative (defined as negative Schistosoma PCR, urine CAA, urine microscopy, and colposcopy imaging) women. Participants with probable FGS (n=25) (defined as the presence of either urine CAA or microscopy in combination with one of four clinical findings suggestive of FGS on colposcope-obtained photographs) were also included, for a total sample size of 212. The concentrations of 17 soluble cytokines and chemokines were quantified by a multiplex bead-based immunoassay. There was no
INTRODUCTION

HIV-1 infection disproportionately affects women in sub-Saharan Africa (1), where areas of high HIV-1 prevalence and Schistosoma haematobium endemicity largely overlap (2). Female genital schistosomiasis (FGS), caused most frequently by S. haematobium egg deposition in the genital tract, has been associated with prevalent HIV-1 infection in cross-sectional studies (3). The presence of S. haematobium eggs in genital tissue is also associated with vascularization (4) and the accumulation of CD4+ lymphocytes and macrophages (5), making the granuloma-associated environment a potential contributor to HIV-1 vulnerability. In addition to modulation of the local cervicovaginal environment, FGS has also been associated with a higher frequency of systemic CD4 T-cells expressing the chemokine receptor CCR5 (6). Tissue-entrapped eggs are also associated with clinically visible FGS-associated manifestations in the cervicovaginal mucosa (7). FGS lesions may breach the intact cervicovaginal immune barrier and are hypothesized to provide an entry point for HIV-1 infection (2, 3). However, the underlying mechanism for potential HIV-1 vulnerability in FGS has not been fully characterized and requires further investigation.

The presence of S. haematobium eggs in human tissue commonly provokes an inflammatory response (5). Cervicovaginal inflammation has emerged as an important risk factor for HIV-1 acquisition, with the presence of increased chemotactic cytokine concentrations, specifically macrophage inflammatory protein-1α (MIP-1α [CCL-3]), MIP-1β [CCL-4], interleukin (IL)-8 [CXCL-8], and interferon-γ inducible protein-10 (IP-10 [CXCL-10]), conferring increased risk (8). Broadly, while pro-inflammatory cytokines are central in recruiting and activating HIV-1 target cells, they also propagate a cascade of downstream cellular processes that enact functions central to HIV-1 pathogenesis (9). The presence of pro-inflammatory cytokines in the female genital tract may also be associated with HIV-1 replication (via stimulation of transcription factors) (10), an increased frequency and activation of HIV-1 target cells (9, 11, 12) and proteomic signatures suggestive of tissue remodeling that may compromise cervicovaginal barrier function (12).

Sexually transmitted infection (STI) and a “non-optimal” cervicovaginal microbiota contribute to a vaginal pro-inflammatory environment (11, 13), and are thus important risk factors for HIV-1 acquisition (14, 15), but elevated cervicovaginal cytokine and chemokine levels have also been detected in their absence (8). In addition to STI and cervicovaginal microbiota, a number of additional biological and behavioral factors influence the levels of detectable soluble immune proteins in the female genital tract, including the presence of semen (16), cervical ectopy (16), use of hormonal contraception (17), menstrual cycle (18), and intravaginal cleansing practices (13, 17).

FGS may be an unmeasured co-factor contributing to cervicovaginal inflammatory signatures in endemic sub-Saharan African populations (8, 11). S. haematobium infection, in the absence of evaluation for genital involvement, has been associated with altered levels of systemic (19) and cervicovaginal cytokines (20). While male genital schistosomiasis has been associated with elevated seminal fluid cytokine concentrations (21), little is known regarding the human cervicovaginal environment in FGS or the role of the immune response. We hypothesize that FGS modulates the cervicovaginal immune environment and that evidence of FGS-associated cervicovaginal inflammation may provide insight into a causal mechanism for the association between FGS and HIV-1. In this cross-sectional study, we evaluate cervicovaginal cytokines and chemokines in women with and without FGS.

METHODS

Study Setting and Participants

The cross-sectional bilharzia and HIV (BILHIV) study was nested in HPTN 071 (PopART), a cluster randomized trial to measure the impact of an HIV-1 combination prevention package (22). HIV-1 incidence was measured in an HPTN 071 (Pop-ART) Population Cohort comprised of one randomly selected adult (18 to 44 years of age) from a random sample of households in each community who provided data and blood samples at baseline, 12, 24, and 36 months (22). After the 36-month HPTN 071 (PopART) visit, trained community workers made home visits between January and August 2018 to women who had expressed interest in the BILHIV study (23). Women
were eligible if they were 18–31 years old, not pregnant, sexually active, and resident in one of the two urban communities that participated in HPTN 071 (PopART) in Livingstone, Zambia. Following written informed consent, the BILHIV study home visit included a questionnaire, genital self-sampling (cervical and vaginal), and a urine specimen, as previously described (23).

**Clinic-Based Sample Collection**

Within days of self-sampling, enrolled women who were not currently menstruating were invited to attend Livingstone Central Hospital cervical cancer screening clinic, where one of two trained midwives performed a cervicovaginal lavage (CVL). Cervicovaginal images were captured with a portable colposcope (MobileODT, Tel Aviv, Israel) and were evaluated by one author (EFK) for the presence of any of the four recognized FGS cervicovaginal manifestations: homogenous yellow sandy patches, grainy sandy patches, rubbery papules, and abnormal blood vessels (24). Women having these manifestations (24) and women with any positive urine or genital *Schistosoma* diagnostic were treated free of charge with 40 mg/kg praziquantel. Testing for STI was not performed at the point-of-care and participants with suspected STI were offered syndromic management, as per local guidelines (25).

**CVL Specimen Processing**

After speculum insertion, normal saline (10 ml) was flushed continuously with a bulb syringe across the cervix and vaginal walls for 1 min and collected from the posterior fornices. CVL fluid was transferred to a 15 ml conical polypropylene tube and stored temporarily in a refrigerator (4°C) on ice until transfer to the laboratory. Protease inhibitor (Cocktail Set I, Calbiochem, Merck Millipore, Darmstadt, Germany) was added to one 1.5 ml aliquot for cytokine and chemokine testing and stored at –80°C, as previously described (17). Specimens were stored for a maximum of 20 months (range 12–20) and were not previously thawed. After thawing, specimens were centrifuged at 320g for 10 min and the supernatant removed. CVL color was visually assessed and a 10 µl aliquot was placed on a Hematix test strip (Siemens, Erlangen, Germany). As per the manufacturer’s instructions, CVL hemoglobin concentrations were recorded after comparing the test strip with color categories representing approximate quantities of erythrocytes (ery) per µl: none, trace, low (25 ery/µL), moderate (80 ery/µL), high (200 ery/µL) (17).

**Multiplex Bead Based Assays**

Luminex MAGPIX® was used to measure concentrations of seventeen soluble cytokines and chemokines using MILLIPLEX Human Cytokine/Chemokine Magnetic Bead kits (Merck Millipore, Darmstadt, Germany) according to the manufacturer’s instructions and recommendations for dilute samples, i.e. CVL. The concentrations of eotaxin (CCL-11), interferon-gamma (IFN-γ), IL-10, IL-13, IL-17A, IL-1α, IL-1β, IL-4, IL-5, IL-6, IL-8 (CXCL-8), IP-10 (CXCL-10), monocyte chemokine protein (MCP-1) (CCL-2), MIP-1α (CCL-3), MIP-1β (CCL-4) and tumor necrosis factor-α (TNF-α) were measured in undiluted CVL in duplicate. The lower limit of detection was between 0.26 and 5.66 pg/ml for the 17 cytokines and chemokines measured (S1 Table).

Using a Luminex MAGPIX® bioanalyzer and xPONENT software (version 4.2), the median fluorescent intensity was measured, background-adjusted, and converted into analyte concentrations using a 5 parameter logistic regression equation to interpolate standard curves. To minimize between-plate variations in cytokine and chemokine concentrations, two specimen controls were included in duplicate across plates and equal proportions of specimens with FGS, probable FGS, and FGS negative were distributed across six 96-well plates (8). Cytokine or chemokine concentrations below the lower limit of quantification (LLOQ) were imputed to be the midpoint of the lowest concentration for each analyte and zero and concentrations above the upper limit of quantification were imputed as the highest concentration for each analyte.

**HIV-1**

Laboratory-based fourth-generation HIV-1 testing (Abbott Architect HIV Ag/Ab Combo Assay). was performed for HPTN 071 (PopART) Population Cohort participants at each study visit (22).

**Circling Anodic Antigen**

A lateral flow assay utilizing up-converting reporter particles for the quantification of CAA was performed on urine samples at the Leiden University Medical Center (LUMC), as previously described (23, 26). CAA levels reflect the burden of live schistosomes and decline after successful treatment with praziquantel (27, 28). Analyzing the equivalent of 417 µl urine (wet reagent, UCAA Ht417), a CAA value of >0.6 pg/ml was considered positive (28).

**PCR for Detection of Schistosoma DNA**

DNA extraction and PCR set up was performed at LUMC, using a custom automated liquid handling station (Hamilton, Switzerland), as previously described (23). DNA was extracted from 200 µl of specimen (cervical swab, vaginal swab, CVL): with QIAamp spin columns (QIAGEN Benelux; Venlo, The Netherlands). Detection of the schistosome-specific internal-transcribed-spacer-2 (ITS2) target was performed by real-time PCR as previously described (23, 29). This PCR does not differentiate between *Schistosoma* species. DNA amplification and detection were performed with the CFX96 Real Time PCR Detection System (BioRad, California, USA). The output in cycle quantification value (Cq), reflecting the parasite-specific DNA load in the tested sample, was analyzed using BioRad CFX software. Parasite DNA loads were categorized by the following pre-specified Cq thresholds: high (Cq<30), moderate (30≤Cq<35), low (35≤Cq<50) and negative (no Cq detected), as previously described (30).

**STI Detection**

We quantified *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Mycoplasma genitalium*, and *Trichomonas vaginalis* using the S-DiaCTNG™ (for *C. trachomatis* and *N. gonorrhoea*) and S-DiaMGTV™ (for *M. genitalium* and *T. vaginalis*) (both Diagenode Diagnostics, Seraing, Belgium) on DNA obtained from cervical swabs at Ghent University (Ghent, Belgium) according to the manufacturer’s instructions. Amplification was
carried out on the LightCycler® 480 and the LightCycler® 480 Software Version 1.5 (Roche, Basel, Switzerland). To quantify each of the target species, standard curves were constructed from a tenfold dilution series of DNA from *C. trachomatis*, *N. gonorrhoeae*, *M. genitalium*, and *T. vaginalis*. Genomic DNA of *C. trachomatis* ATCC VR-571B, *T. vaginalis* ATCC 50148 and *M. genitalium* G37 was obtained from the American Type Culture Collection (ATCC). Genomic DNA from *N. gonorrhoeae* was obtained after culturing strain ATCC 43069 at 35°C ±1°C for 5 days on chocolate agar (Becton Dickinson) and extracting DNA from colonies using Roche High Pure DNA Purification kit (Roche). All DNA concentrations were determined using NanoDrop (Thermo Fisher Scientific, Erembodegem, Belgium). The genomic concentrations were calculated using the described genomic sizes of the type strains. Both the standard curves and samples were run in duplicate. The number of bacteria and protozoan concentration was expressed as genome equivalents per ml (geq/ml) (31).

**Ethical Considerations**

The study was approved by the University of Zambia Biomedical Research Ethics Committee (reference 011-08-17), the Zambia National Health Research Authority and the London School of Hygiene and Tropical Medicine Ethics Committee (reference 14506). Permission to conduct the study was given by Livingstone District Health Office and the superintendent of Livingstone Central Hospital.

**FGS Definitions**

The FGS categories were defined by the results of four investigations: *Schistosoma* PCR (on DNA extracted from cervical swabs, vaginal swabs, or CVL), colposcopy image review, urine CAA, and urine microscopy. Participants were grouped by the outcomes of their diagnostic tests into three mutually exclusive categories. FGS was defined as at least one positive *Schistosoma* PCR on a genital specimen (cervical swab, vaginal swab and/or CVL). In participants with a negative *Schistosoma* PCR, probable FGS was defined as the presence of urinary schistosomiasis, detected with either urine CAA or urine microscopy, in combination with one of four clinical findings suggestive of FGS on any colposcope-obtained photograph (24). FGS negative was defined as negative results on all diagnostic assays. Participants with results for all available diagnostic tests who were *Schistosoma* genital PCR negative and did not qualify for the FGS, probable FGS, or FGS negative groups (n=190) were not eligible for study inclusion (Figure 1). All participants with FGS (n=28) who attended clinic follow up and provided a CVL specimen and all participants with probable FGS (n=25) were selected for measurement of cytokines and chemokines in CVL samples. Three FGS negative participants were selected for every FGS and probable FGS participant, using a random number generator. The FGS negative participants were frequency matched by age to the participants with FGS.

**STATISTICAL METHODS**

Participant characteristics were summarized by median and interquartile range (IQR) for continuous variables, and by frequency and percentage for categorical variables. Differences in characteristics between the FGS categories were evaluated using Fisher’s exact and chi-squared tests. For cytokines or chemokines with at least 70% of sample results above the LLOQ, differences in median cytokine or chemokine

![FIGURE 1](Download PDF)
concentrations between FGS categories were evaluated using the Wilcoxon-Mann-Whitney test. Cytokines or chemokines with <70% of the sample results above the LLOQ were analyzed as binary variables (presence/absence) and compared between FGS categories using Fisher’s exact and chi-squared tests. To correct for multiple comparisons we used a Monte Carlo simulation approach with 1000 replicates (32): for each replicate the labels of the groups being compared were randomly permuted and statistical tests were repeated, to generate empirical p-values. For further analysis, cytokine or chemokine concentrations with at least 70% of sample results above the LLOQ were log-transformed to normalize their distribution, and linear regression was performed to evaluate the association between FGS and mean cytokines or chemokine in univariable and multivariable analysis and expressed with 95% confidence intervals. For the cytokines with <70% of the sample results above the LLOQ (IL-5, IL-13, IL-15, and TNF-α), logistic regression was used to evaluate the association between FGS and detectable cytokine concentrations and expressed with 95% confidence intervals. To adjust for potential confounders, we developed a causal conceptual framework (S1 Figure) to inform our minimal adjustment set. For the cytokines and chemokines analyzed by linear regression, we adjusted for age, education, community of residence, and the presence of any STI. Since hormonal contraception is associated with the outcome, but not the exposure (FGS), it was also included in the multivariable model to improve precision. For the cytokines analyzed by logistic regression (IL-5, IL-13, IL-15, and TNF-α), due to the relatively low number of participants with concentrations above the LLOQ, these cytokines were adjusted for age and STI. Because HIV-1 status and the presence of hemoglobin in CVL are both potentially influenced by FGS (2), and may also affect CVL cytokine or chemokine concentrations, these variables were considered to be on the causal pathway and were not included in the final multivariable model (S1 Figure).

Our primary hypothesis was that FGS modulates the cervicovaginal microenvironment with a secondary hypothesis that FGS may increase the concentration of selected HIV-1 acquisition associated chemokines (8). Thus, our primary analysis focused on the detection of Schistosoma DNA in the genital tract, comparing FGS vs FGS negative participants. As a secondary aim, participants with FGS and probable FGS were combined and compared with the FGS negative group.

Spearman’s rank correlation was used to evaluate the strength of the relationship between individual analytes (S2 Figure). Since many cytokines and chemokines were correlated, we performed Principal Components Analysis (PCA) on the log-transformed analyte concentrations to generate new uncorrelated “components” that were linear combinations of the initial variables. The first two principal components captured the majority of the variability in the data and were taken forward for additional comparisons between FGS groups (S2 Table).

To evaluate the possible association between intensity of FGS presentation and changes in cytokine or chemokine concentrations, two ad hoc exploratory analyses were performed: (1) participants with ≥2 genital samples with detectable Schistosoma DNA levels were compared with those in the FGS negative group, (2) participants with a moderate/high genital Schistosoma DNA concentration (defined by a Cq <35 in at least one of the three examined samples) were compared with those in the FGS negative group.

In this study we measured the concentration of cytokines and chemokines in CVL. However, the presence of hemoglobin in CVL may serve as a surrogate marker for the presence of systemic and/or menstrual blood in the cervicovaginal environment. HIV-1 status and the presence of hemoglobin in CVL are potentially influenced by FGS (2), but may also independently affect cytokines and chemokine concentrations. Thus, we performed two sensitivity analyses, one compared participants with FGS with those in the FGS negative group after excluding the participants who were HIV-1 positive from both groups. A second sensitivity analysis compared participants with FGS with those in the FGS negative group after excluding the participants whose CVL sample displayed the presence of hemoglobin. Data were analyzed using STATA 15.1 (Stata Corporation, College Station, TX). P-values less than 0.05 were classified as demonstrating “evidence” of an association and p-values between 0.05 and 0.10 were classified as demonstrating “some evidence” of an association.

RESULTS

A total of 603 eligible women were enrolled and 212 (35.2%) were included in this study (Figure 1). Overall, 13.2% (28/212) of women had FGS, defined by a positive genital Schistosoma PCR from any of the following sites: 8.5% (18/212) cervical swab, 6.6% (14/212) vaginal swab, and 6.6% (14/212) CVL. Probable FGS was detected in 25 women, and 61.1% (159/262) of the women who were negative on all diagnostic tests were randomly selected for inclusion in this study.

Baseline Characteristics

The majority of the participants had received at least secondary education, were using hormonal contraception, and had detectable hemoglobin in their CVL. At the conclusion of HPTN 071 (PopART), HIV-1 prevalence was 17.0% (36/212) among the women included in this study and one-third of the women had FGS, defined as demonstrating some evidence of an association and p-values between 0.05 and 0.10 were classified as demonstrating “some evidence” of an association.
attainment (p=0.04), employment (p=0.05), and marital status (p=0.04) with participants in the probable FGS group more likely to be older, have a primary school education, be employed, and be married than FGS and FGS negative participants. Other characteristics were similar by FGS status.

**Expression Profiles of Cytokines and Chemokines in CVL**

The mean, median and range of concentrations (pg/ml) of the 17 cytokines and chemokines measured are displayed in S1 Table. The distributions of log-transformed concentrations (median

---

**TABLE 1 | Baseline characteristics of the 212 study participants by female genital schistosomiasis (FGS) status.**

| Socio-behavioral Characteristics | FGS* % (n = 28) | FGS Probable* % (n = 25) | FGS Negative* % (n = 159) | p-value |
|----------------------------------|-----------------|---------------------------|---------------------------|--------|
| **Age in years**                 |                 |                           |                           |        |
| Median (IQR)                     | 22 (20–24)      | 27 (23–31)                | 23 (22–24)                | 0.001  |
| **Marital Status**               |                 |                           |                           |        |
| Single                           | 42.9 (12)       | 16.0 (4)                  | 45.9 (73)                 | 0.04   |
| Married or Cohabitating          | 57.1 (16)       | 80.0 (20)                 | 50.9 (81)                 |        |
| Divorced or Separated            | 0.0 (0)         | 4.0 (1)                   | 3.1 (5)                   |        |
| **Education (highest level)**    |                 |                           |                           |        |
| None/Any Primary School          | 32.1 (9)        | 48.0 (12)                 | 22.0 (35)                 | 0.04   |
| Any Secondary School            | 67.9 (19)       | 52.0 (13)                 | 70.4 (112)                |        |
| Training in a Trade              | 0.0 (0)         | 0.0 (0)                   | 0.0 (0)                   |        |
| **Employment Status**            |                 |                           |                           |        |
| Working                          | 14.3 (4)        | 44.0 (11)                 | 25.8 (41)                 | 0.05   |
| Not Working                      | 85.7 (24)       | 56.0 (14)                 | 74.2 (118)                |        |
| **Current Water Contact**        |                 |                           |                           |        |
| None                             | 100.0 (28)      | 84.0 (21)                 | 86.8 (138)                | 0.01   |
| Any                              | 0.0 (0)         | 16.0 (4)                  | 13.2 (21)                 |        |
| **Childhood Water Contact**      |                 |                           |                           |        |
| None                             | 14.3 (4)        | 24.0 (6)                  | 32.1 (51)                 | 0.1    |
| Any                              | 85.7 (24)       | 76.0 (19)                 | 67.9 (108)                |        |
| **Community of Residence**       |                 |                           |                           |        |
| Community A                      | 75.0 (21)       | 80.0 (20)                 | 41.5 (66)                 | <0.001 |
| Community B                      | 25.0 (7)        | 20.0 (6)                  | 58.5 (93)                 |        |

**Sexual behavior characteristics and STI.**

|                          | FGS* % (n = 28) | FGS Probable* % (n = 25) | FGS Negative* % (n = 159) | p-value |
|--------------------------|-----------------|---------------------------|---------------------------|--------|
| **Ever pregnant**        | No*             | 7.1 (2)                   | 4.0 (1)                   | 0.04   |
|                          | Yes             | 92.9 (26)                 | 96.0 (24)                 | 82.4 (131) |
| **Age at sexual debut**  | Median (IQR)    | 16 (15–18)                | 17 (15–18)                | 0.09   |
| **Lifetime sexual partners** | Median (IQR)   | 3 (2–4.5)                 | 2 (1–3)                   | 0.3    |
| **Currently Sexually Active** | Yes*           | 10.7 (3)                  | 8.0 (2)                   | 0.6    |
|                          | No**            | 89.3 (25)                 | 92.0 (23)                 | 83.5 (132) |
| **Contraceptive Method**  | Immplant        | 7.1 (2)                   | 8.0 (2)                   | 0.1    |
|                          | Injectible      | 53.6 (15)                 | 48.0 (12)                 | 0.9    |
| **Oral Contraceptive Pill** | Oral Contraceptive Pill | 3.6 (1) | 12.0 (3) | 6.3 (10) |
|                          | Condoms         | 10.7 (3)                  | 20.0 (5)                  | 0.7    |
| **HIV-1**                | Not Detected    | 82.1 (23)                 | 80.0 (20)                 | 0.9    |
|                          | Detected        | 17.9 (5)                  | 20.0 (5)                  |        |
| **Chlamydia trachomatis** | Not Detected    | 89.3 (25)                 | 96.0 (24)                 | 0.7    |
|                          | Detected        | 10.7 (3)                  | 4.0 (1)                   |        |
| **Neisseria gonorrhoea**  | Not Detected    | 100.0 (28)                | 96.0 (24)                 | 0.4    |
|                          | Detected        | 0.0 (0)                   | 4.0 (1)                   |        |
| **Mycoplasma genitalium** | Not Detected    | 100.0 (28)                | 96.0 (24)                 | 0.5    |
|                          | Detected        | 0.0 (0)                   | 4.0 (1)                   |        |
| **Trichomonas vaginalis** | Not Detected    | 67.9 (19)                 | 68.0 (17)                 | 0.3    |
|                          | Detected        | 32.1 (9)                  | 32.0 (8)                  |        |
| **Any STI**              | Not Detected    | 64.3 (18)                 | 56.0 (14)                 | 0.5    |
|                          | Detected        | 35.7 (10)                 | 44.0 (11)                 |        |

**Clinical Findings**

|                          | FGS* % (n = 28) | FGS Probable* % (n = 25) | FGS Negative* % (n = 159) | p-value |
|--------------------------|-----------------|---------------------------|---------------------------|--------|
| **Hemoglobin in CVL (ery/µL)** | None            | 28.6 (8)                  | 25.0 (6)                  | 36.1 (57) |
|                          | Trace           | 17.9 (5)                  | 12.5 (3)                  | 15.2 (24) |
|                          | 2               | 32.1 (9)                  | 16.7 (4)                  | 17.7 (28) |
|                          | 80              | 3.6 (1)                   | 16.7 (4)                  | 17.1 (27) |
|                          | 200             | 17.9 (5)                  | 29.2 (7)                  | 13.9 (22) |
| **Colposcopy Findings**   | Sandy Patches   | 22.2 (8)                  | 76.0 (19)                 | 0.0 (0) |
| **Rubbery Papule**        | 0.0 (0)         | 4.0 (1)                   | 0.0 (0)                   |        |
| **Abnormal Blood Vessels** | 22.2 (8)       | 24.0 (6)                  | 0.0 (0)                   |        |
| **No FGS findings**      | 56.0 (15)       | 0.0 (0)                   | 100.0 (159)               |        |

Fisher’s exact test.

Self-reported history of ever having a pregnancy, participants reporting “no answer” (n=1, FGS negative group) are not shown.

Participants reporting “no answer” (n=1, FGS negative group) are not shown.

Hemoglobin was measured with Hemastix® test strips using a color chart measured in erythrocytes (ery) per µl.

Colposcopy findings were included in the study inclusion criteria, so no p-value is shown; one participant with FGS did not have interpretable colposcopy results. Images were interpreted based on the presence of sandy patches or ruberry papules, if these findings were present, the additional finding of abnormal blood vessels was not noted.
and interquartile range) of the 17 cytokines and chemokines are displayed by FGS status in Figure 2.

FGS Signature - Crude and Adjusted Expression Profiles

Compared to FGS negative women, IL-5 was elevated in participants with FGS (Table 2, Figure 2, crude p-value 0.02, p-value after adjustment for multiple testing 0.14). Compared to FGS negative women, women with FGS had similar expression profiles of chemokines that predicted HIV-1 acquisition risk in a South African study (MIP-1α [CCL-3], MIP-1β [CCL-4], IL-8 [CXCL-8], and IP-10 [CXCL-10]) (8). This was confirmed after adjusting for age, STI, community of residence, education, and use of hormonal contraception (Figure 3). Principal Components Analysis identified that two Principal Components accounted for 60.0% of the variability in the data (S2 Table). Taken forward, there was no difference in mean scores for these two Principal Components by FGS status (S3 Figure).

When the FGS and probable FGS groups were combined, in the crude analysis (S4 Figure) and after adjustment for possible confounders, participants with FGS/probable FGS had higher concentrations of TNF-α than FGS negative participants (S5 Figure, p=0.03, p-value adjusted for multiple testing 0.09).

Exploratory Analyses – Clinical Disease Burden

In an exploratory analysis of participants (n=15) with a higher FGS burden defined as ≥2 Schistosoma PCR positive genital specimens, there was evidence of an elevated concentration of cytokines IL-4, IL-5, IL-13, IL-15 compared to FGS negative women (Figure 4). This association remained after adjusting for potential confounders (Figure 5). After adjustment for multiple comparisons strong evidence remained that IL-4 (multiple testing adjusted p=0.037) and IL-5 (multiple testing adjusted p=0.001) were associated with FGS.

Exploratory Analyses – Schistosoma DNA Concentration

In a further exploratory analysis of women (n=15) with FGS and moderate or high genital Schistosoma DNA concentration (Schistosoma PCR Cq<35) there was evidence that the concentrations of cytokines IL-1α, IL-4, IL-5, IL-13, IL-15, and TNF-α were elevated in participants with Schistosoma PCR Cq<35 compared to FGS negative women (Figure 6). After adjustment for potential confounders, evidence remained that IL-4, IL-5, IL-15, and TNF-α were elevated in participants with moderate/high Schistosoma DNA concentration compared to FGS negative women (Figure 7). After adjustment for multiple comparisons, strong evidence remained that the associations for IL-5 (multiple testing adjusted p=0.001) and TNF-α (multiple testing adjusted p=0.045) were unlikely to have occurred by chance. When comparing the participants with moderate/high Schistosoma DNA concentration and the participants with ≥2 PCR positive genital specimens, 11 women overlapped between groups.

Sensitivity Analyses – HIV-1 and CVL Hemoglobin

We performed sensitivity analyses removing participants with HIV-1 infection or the presence of hemoglobin in CVL from the comparison between FGS and negative FGS groups. When n=31 participants with HIV-1 from the FGS and FGS negative groups were excluded from the analysis, there was no difference in the expression profiles of cytokines or chemokines in women with FGS compared to FGS negative women (S6 Figure). When n=139 participants with any detectable hemoglobin in CVL were removed from the analysis (S7 Figure), there was some evidence that concentrations of IL-17A and IL-8 (CXCL-8) were higher in participants with FGS (n=8) compared to the FGS negative group (n=57) (p=0.13 after allowing for multiple testing).

DISCUSSION

This study is the first to describe expression patterns of cytokines and chemokines in human FGS, diagnosed by Schistosoma PCR from vaginal swabs, cervical swabs, and CVL. The immune environment in helminth infection is often characterized as T helper 2 (Th2) biased and involves the orchestration of cytokines (IL-4, IL-5, IL-13), antibodies, and regulatory cells (33). We did not detect an association between FGS, defined as Schistosoma DNA detected in genital PCR specimens, and a change in

![FIGURE 2](image-url) Median with interquartile range of the log-transformed crude concentrations of eleven cytokines and six chemokines in cervicovaginal lavage of participants with (FGS: n=28) and without female genital schistosomiasis (FGS negative: n=159). FGS – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative genital PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging. *p-value after adjustment for multiple testing with a Monte-Carlo simulation approach, p=0.14 p-value symbol legend. **p < 0.05.
expression pattern of cytokines or chemokines in CVL including those associated with HIV-1 acquisition in a South African study (8). Compared to the FGS negative participants, the Th2 cytokine IL-5 was elevated in the participants with FGS, however after adjustment for multiple comparisons we cannot exclude that this finding may be due to chance.

Previous work on male genital schistosomiasis has shown that infection intensity, defined by seminal egg count, is strongly associated with elevated seminal cytokine concentrations including Th2 (IL-4), regulatory (IL-10), Th1 (IFN-γ) and pro-inflammatory (TNF-α) cytokines (21). Thus, we evaluated FGS burden by performing two exploratory analyses, the results of which show a Th2 expression pattern. First, we investigated the association between multiple PCR-positive genital specimens as a potential proxy marker of higher FGS burden in 15 women with infection intensity, de infection (36). There was evidence for higher concentrations of IL-5 after adjustment for multiple comparisons across both exploratory analyses. IL-5 induces eosinophil maturation and an IL-5 response to Schistosoma antigens has been associated with microhematuria in children with S. haematobium infection (36). There was evidence for higher concentrations of IL-4 after adjustment for multiple comparisons in the exploratory analyses of participants with moderate/high Schistosoma DNA concentrations after adjustment for potential confounders and multiple comparisons, which show a Th2 expression pattern. Second, we investigated whether Schistosoma DNA concentrations in genital samples might be associated with a change in cytokine concentrations in 15 participants with FGS and moderate/high genital Schistosoma DNA concentrations (defined as Schistosoma PCR Cq<35). After adjusting for potential confounders, the exploratory analyses found a higher cervicovaginal Th2 cytokine response (IL-4, IL-5, IL-13) in participants with ≥ two positive specimens and participants with higher genital Schistosoma DNA concentrations. This is not unexpected considering that a Th2 biased immune response is associated with helminth infection (33) and S. haematobium exposure in both human and murine hosts (34, 35). There was evidence for higher concentrations of IL-5 after adjustment for multiple comparisons across both exploratory analyses. IL-5 induces eosinophil maturation and an IL-5 response to Schistosoma antigens has been associated with microhematuria in children with S. haematobium infection (36). There was evidence for higher concentrations of IL-4 after adjustment for multiple comparisons in the exploratory analyses of multiple PCR-positive genital specimens for Schistosoma DNA. In the Th2 response, IL-4 directly regulates T-cell differentiation and proliferation (37). The finding of elevated levels of pro-inflammatory TNF-α in the exploratory analyses of participants with moderate/high Schistosoma DNA concentrations after adjustment for potential confounders and multiple comparisons, suggests that FGS may promote a mixed Th2 and pro-inflammatory response. TNF-α may be associated with Schistosoma granuloma formation (38) and in children with S. haematobium infection, TNF-α production has been associated with ultrasound-determined urinary bladder morbidity (39).

We found IL-13 and IL-15 to be associated with a higher clinical FGS burden and higher genital Schistosoma DNA concentrations after adjusting for potential confounders, although these associations no longer remained after adjustment for multiple comparisons. Predominantly produced by macrophages, IL-15 is

### Table 2

| Analyte | % (n) above LLOQ | FGS Negative (n=159) | FGS n=28 | p-value | OR FGS vs FGS Negative | p-value |
|---------|-----------------|----------------------|----------|---------|------------------------|---------|
| Eotaxin | 73.6 (156)      | 3.85                 | 3.92     | 0.22    | 1.48 (0.95–2.32)       | 0.08    |
| Interferon-γ | 84.0 (178) | 0.91                 | 0.80     | 0.71    | 0.98 (0.64–1.51)       | 0.94    |
| IL-10   | 90.1 (191)      | 0.98                 | 1.33     | 0.75    | 1.02 (0.65–1.61)       | 0.93    |
| IL-17A  | 93.4 (198)      | 1.38                 | 1.86     | 0.14    | 1.37 (0.85–2.23)       | 0.64    |
| IL-1α   | 99.5 (211)      | 44.00                | 73.08    | 0.17    | 1.24 (0.63–2.44)       | 0.19    |
| IL-1β   | 93.4 (198)      | 9.79                 | 9.05     | 0.38    | 1.59 (0.56–4.51)       | 0.52    |
| IL-4    | 96.2 (204)      | 2.79                 | 3.42     | 0.20    | 1.41 (0.94–2.12)       | 0.09    |
| IL-6    | 87.7 (186)      | 2.85                 | 3.81     | 0.67    | 1.14 (0.56–2.35)       | 0.71    |
| IL-8    | 100.0 (212)     | 526.03               | 566.68   | 0.33    | 1.29 (0.75–2.19)       | 0.34    |
| IP-10   | 100.0 (212)     | 101.86               | 128.38   | 0.42    | 1.34 (0.68–2.66)       | 0.39    |
| MCP-1   | 100.0 (212)     | 29.04                | 24.68    | 0.79    | 0.98 (0.53–1.83)       | 0.95    |
| MIP1-α  | 98.1 (208)      | 4.23                 | 3.61     | 0.15    | 0.62 (0.36–1.08)       | 0.09    |
| MIP1-β  | 84.0 (177)      | 1.32                 | 1.64     | 0.67    | 1.05 (0.54–2.05)       | 0.89    |

FGS, female genital schistosomiasis; GMR, geometric mean ratio; LLOQ, lower limit of quantification.

*FGS – Schistosoma PCR-positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative Schistosoma PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging.

**Concentrations are reported in pg/ml.

*n=25 Participants with probable FGS are not shown.

†Rank sum p-value.

‡Chi-squared p-value.

§Adjusted for age and STI.

¶Adjusted for age and STI.

#Likelihood ratio test p-value.
FIGURE 3 | Comparison of the concentration or presence of eleven cytokines and six chemokines in cervicovaginal lavage of participants with (FGS, n=28) and without (FGS negative, n=159) female genital schistosomiasis. (A) Concentrations of eotaxin, IFN-γ, IL-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, MCP-1, MIP-1α, and MIP-1β were compared between FGS and FGS negative participants by linear regression and adjusted for age, community of residence, education, presence of sexually transmitted infection and hormonal contraceptive use, with results shown as geometric mean ratios with 95% CI. (B) Presence/absence of IL-5, IL-13, IL-15 and TNF-α were compared by logistic regression and adjusted for age and sexually transmitted infection, with results shown as odds ratio with 95% CI. The line at 1 indicates the value at which there is no difference between the FGS and FGS negative groups. p-value symbol legend: *p < 0.1 **p < 0.05.

Female genital schistosomiasis – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative genital PCR and negative urine circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging.

FIGURE 4 | Median with interquartile range of the log-transformed crude concentrations of eleven cytokines and six chemokines in cervicovaginal lavage by FGS burden (Schistosoma PCR in ≥ two genital specimens; n=15, FGS negative; n=159)². FGS – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative Schistosoma PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging. *p-value after adjustment for multiple testing with a Monte-Carlo simulation approach, p < 0.001. p-value legend *p < 0.1 **p < 0.05.
FIGURE 5 | Comparison of the concentrations or presence of eleven cytokines and six chemokines in cervicovaginal lavage in participants with greater FGS burden (Schistosoma PCR positive in ≥ two genital specimens, n=15) and participants without female genital schistosomiasis (n=159). (A) Concentrations of eotaxin, IFN-γ, IL-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, MCP-1, MIP-1α, and MIP-1β were compared between FGS and FGS negative participants by linear regression adjusted for age, community of residence, education, presence of sexually transmitted infection and hormonal contraceptive use, with results shown as geometric mean ratios with 95% CI. (B) Presence/absence of IL-5, IL-13, IL-15 and TNF-α were compared by logistic regression and adjusted for age and sexually transmitted infection, with results shown as odds ratio with 95% CI. The line at 1 indicates the value at which there is no difference between the FGS and FGS negative groups. p-value symbol legend: *p <0.1 **p <0.05.

female genital schistosomiasis – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative Schistosoma PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging.

FIGURE 6 | Median with interquartile range of the log-transformed crude concentrations of eleven cytokines and six chemokines in cervicovaginal lavage by FGS burden (Schistosoma DNA concentration Cq <35 in any genital specimen, n=15, FGS negative:n=159). FGS – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative Schistosoma PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging. p-value after adjustment for multiple testing with a Monte-Carlo simulation approach, p=0.001 p-value symbol legend: *p < 0.1 **p < 0.05.
a pro-inflammatory, immunomodulatory cytokine that stimulates T, B, and Natural Killer cells (40). Lower levels of IL-15 have been reported in the cervicovaginal environment of women with *S. haematobium* infection, with between-study differences potentially related to genital *Schistosoma* DNA detection (20). The Th2 cytokine IL-13 is thought to be an important driver of collagen deposition in the *Schistosoma* egg granuloma (41), ultimately leading to fibrosis. Indeed, IL-13 expression levels have been associated with the severity of hepatic fibrosis in *S. mansoni* infection (42). The exploratory sub-group analyses thus support previous work describing that *S. haematobium* may modulate the genital immune environment (20, 21). As a protracted Th2 response is often associated with schistosomiasis-related morbidity (43), our study findings warrant further investigation. The current study included many statistical tests, and these were allowed for using a permutation testing approach. However, we cannot exclude the possibility that some of the associations are due to chance. Thus, it may be more instructive to consider patterns in cytokine signatures (Th2, pro-inflammatory) across analyses, rather than interpreting significance testing for any one cytokine in isolation. Although strong evidence remained for some of the associations found in the exploratory analyses of FGS burden after adjusting for potential confounders and multiple comparisons, as exploratory analyses, these findings should be viewed as hypothesis generating.

Many hypotheses have been put forward regarding the mechanism of HIV-1 vulnerability in women with FGS, with evidence of both local mucosal factors and systemic immunomodulation (2, 4–6). In a South African study, women who acquired HIV-1 in the CAPRISA tenofovir gel trial had higher concentrations of the chemotactic cytokines MIP1-α (CCL-3), MIP1-β (CCL-4), IL-8 (CXCL-8), and IP-10 (CXCL-10) prior to seroconversion than women who did not seroconvert (8). In the current study, the concentrations of the aforementioned chemotactic chemokines were not higher in women with FGS compared to the FGS negative group. While not yet studied in *S. haematobium*, herpes simplex virus type 2 infection stimulates...
TNF-α production in dendritic cells, enhancing the expression of the chemokine co-receptor CCR5 and stimulating HIV-1 replication (44). Further research is needed to elucidate mechanisms for the association of FGS with HIV-1 vulnerability, and these may include schistosome-related impact on mucosal and systemic immunity, including the activation of CD4 trafficking to the genital mucosa (45), or modification in systemic (46) or cervical (20) gene expression, specifically related to the regulation of transcription, the inflammatory response or tissue fibrosis.

Cervical tissue containing S. haematobium eggs is more vascular (4) compared to non-egg containing tissue. Clinically, these abnormal blood vessels can be found encircling sandy patches and contact bleeding has been associated with FGS (47). Thus, FGS studies using cervicovaginal lavage are likely to be burdened by the presence of hemoglobin (48). Since HIV-1 and the presence of hemoglobin in CVL are potentially on the causal pathway between FGS and a change in cytokine or chemokine concentrations, we were unable to adjust for these possible confounding variables in a multivariable model. A sensitivity analysis removing participants with HIV-1 showed no change in the association between FGS and cytokine or chemokine concentrations. HIV-1 infection modulates the cervicovaginal immune environment in women with detectable cervicovaginal HIV-1 RNA (49) and we did not have complete data on plasma viral load in this cohort. Additionally, the analysis to remove participants with any CVL hemoglobin detection was limited by loss of power. Once participants who had any CVL hemoglobin were removed from the analysis, there was evidence of higher concentrations of IL-17A and IL-8 (CXCL-8) in participants with FGS (n=8) compared with FGS negative participants (n=57). This finding, however, was less robust after adjusting for multiple comparisons. Considering the potential loss of the FGS phenotype when excluding women with CVL hemoglobin and the small and likely non-representative sample size, these findings should be interpreted with caution.

Our study has a number of strengths. We are the first to describe the cervicovaginal immune environment in women with Schistosoma PCR-defined FGS and this study illustrates the importance of evaluating FGS burden. Defining FGS based on the detection of Schistosoma DNA in the female genital tract by PCR results provides a higher certainty of genital involvement and a quantitative reference standard compared to visually-diagnosed FGS or the use of urine diagnostics alone. Due to the small numbers of FGS cases, we employed a matching strategy wherein participants with FGS were frequency matched with FGS negative participants. To reduce the risk of selection bias, we used a random number generator to randomly select controls and matched on age group. Multiplex bead-based assays have a precedent for use in CVL (8, 11, 14, 17) and we examined a variety of soluble immune proteins including chemokines, Th1, Th2, pro-inflammatory and regulatory cytokines for a broad overview of the cervicovaginal immune environment. Another strength is that we present both crude and adjusted outcomes to facilitate comparisons in future study settings.

While our study has multiple strengths, there are also some relevant limitations. The study was conducted in a low-prevalence area and the number of FGS cases in the main and exploratory analyses is small. We selected a sub-sample of the cohort for multiplex bead-based immunoassays. This may limit the generalizability of the proportions presented for demographic variables or FGS and schistosomiasis prevalence. Secondly, we were unable to measure a number of behavioral and biological factors that also affect cervicovaginal soluble immune protein expression patterns including the presence of bacterial vaginosis (13), HSV-2 status (11), intra-vaginal cleansing practices (17), vaginal pH, menstrual cycle phase (18), body weight (50) and recent sexual contact (16). It is also undetermined how these same factors may influence Schistosoma DNA concentrations. Thus, we cannot exclude unmeasured and residual confounding. Additionally, due to the cross-sectional study design, we were also unable to assess the long-term impact of the cytokine expression profiles or to determine the duration of FGS infection. Though the cytokines and chemokines we measured are well-known biomarkers for inflammation and disease, it is a limitation that we did not have companion flow cytometry, biopsy, or transcriptomic data for a more detailed evaluation of cellular and histological processes. Additionally, CVL is dilute and the concentrations of the cytokines and chemokines we measured were small. This could potentially be ameliorated in future studies with the use of a menstrual cup to collect genital fluid (51).

FGS is thought to be a chronic infection of the female genital tissue, with initial infection and the development of genital lesions occurring during childhood water contact (52) that persist into adulthood, often even despite treatment with praziquantel (53). The chronicity of FGS lesions may have an impact on the cervicovaginal immune environment and a longitudinal study is needed to document the FGS immune environment in a spectrum of FGS stages before interventions can be based on our exploratory observations. Further work investigating the cervicovaginal immune environment in FGS may impact diagnostic, preventative and therapeutic options as well as potentially providing additional information on HIV-1 vulnerability.

In conclusion, this study does not show a difference in the cervicovaginal immune environment by Schistosoma PCR-defined FGS status. However, two exploratory analyses suggest that there may be a relationship between higher genital Schistosoma DNA concentrations or multiple PCR positive genital specimens and a Th2 and pro-inflammatory modulation of the cervicovaginal immune environment, as measured by elevated cytokine concentrations. FGS may alter the female genital tract immune environment, but a larger longitudinal study in a high FGS prevalence area is needed to better define the role of FGS in HIV-1 acquisition.

**DATA AVAILABILITY STATEMENT**

Anonymised data from the HPTN 071 (PopART) study that support the findings of this study can be made available by the HPTN 071 (PopART) study team, subject to an application process. Further details can be obtained from AB (amaya.bustinduy@lshtm.ac.uk).
ETHICS STATEMENT

The studies involving human participants were reviewed and approved by University of Zambia Biomedical Research Ethics Committee (reference 011-08-17), the Zambia National Health Research Authority and the London School of Hygiene and Tropical Medicine Ethics Committee (reference 14506). Permission to conduct the study was given by Livingstone District Health Office and the superintendent of Livingstone Central Hospital. The participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

AS – conceptualization, data curation, formal analysis, investigation, BILHIV project administration, visualization, writing - original draft preparation. EW – conceptualization, data curation, formal analysis, supervision, visualization, writing - original draft preparation. CP – investigation, writing – review and editing. CRP – BILHIV project administration, writing – review and editing. TM – investigation, writing – review and editing. EK – investigation, writing – review and editing. MM – investigation, writing – review and editing. JM – investigation, writing – review and editing. MMM – conceptualization, resources, writing – review and editing. JC – conceptualization and resources. GD – investigation, writing – review and editing. PC – investigation, writing – review and editing. HA – resources, writing – review and editing. RH – resources, supervision, writing – review and editing. IH – resources, supervision, writing – review and editing. GM – resources, writing – review and editing. PC – investigation, writing – review and editing. LL – investigation, writing – review and editing. LC – investigation, writing – review and editing. SF – conceptualization, supervision, writing original draft preparation. AB – conceptualization, funding acquisition, supervision, visualization, writing - original draft preparation. All authors contributed to the article and approved the submitted version.

FUNDING

AB received funding from the Wellcome Trust (Award 205954/Z/17/Z) and the Dowager Countess Eleanor Peel Trust. EW and RH received funding from MRC Grant Reference MR/K012126/1, and SF received salary from MRC Grant Reference MR/N023692/1. These awards are jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 program supported by the European Union. HPTN 071 (PopART) was supported by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements UM1-AI068619, UM1-AI068617, and UM1-AI068613, with funding from the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR); the International Initiative for Impact Evaluation with support from the Bill and Melinda Gates Foundation; the NIAID, the National Institute on Drug Abuse, and the National Institute of Mental Health, all part of the National Institutes of Health. EK was supported by South-Eastern Regional Health Authority, Norway project #2016055.

ACKNOWLEDGMENTS

We would like to thank the study participants for their contribution to this work. We recognize the BILHIV Study team, supervisor Namakau Chola, and field workers Ethel Mwansa, Mwiingana Lukonga, Ruth Mwanza, Mervis Kantukaleza, and Judith Lungu for their hard work, enthusiasm, and commitment. We also acknowledge tremendous support in Livingstone from Clement Mwakamui (Zambart). We recognize Kevin Tetteh (LSHTM) for generously providing resources and support to run the multiplex bead-based assays. We gracefully acknowledge Eric AT Brienen (LUMC) for performing the Schistosoma PCR analysis and Claudia J. de Dood (LUMC) and Pysje T. Hoekstra (LUMC) for performing the CAA analysis. We would like to thank Jo-Ann Passmore (University of Cape Town), Lindi Masson (Burnett Institute), Michael Hsieh (Children’s National), and Hazel Dockrell (LSHTM) for instructive consultations regarding analyte selection. We are grateful to Michael Hsieh (Children’s National) for his critical review of the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.620657/full#supplementary-material

REFERENCES

1. UNAIDS. UNAIDS Global AIDS Update, Communities at the Centre 2019 . Available at: https://www.unaids.org/en/20190716_GR2019_communities (Accessed November 2, 2020).
2. Sturt AS, Webb EL, Francis SC, Hayes RJ, Bustinduy AL. Beyond the barrier: Female Genital Schistosomiasis as a potential risk factor for HIV-1 acquisition. Acta Trop (2020) 209:105524. doi: 10.1016/j.actatropica.2020.105524
3. Kjetland EF, Ndlovu PD, Gomo E, Mdlula T, Mdzii N, Gwanzura L, et al. Association between genital schistosomiasis and HIV in rural Zimbabwean women. AIDS (2006) 20(4):593–600. doi: 10.1097/01.aids.0000210614.45212.0a
4. Jourdan PM, Roald B, Poggensee G, Gundersen SG, Kjetland EF. Increased vascularity in cervicovaginal mucosa with Schistosoma haematobium infection. Plos Negl Trop Dis (2011) 5(6):e1170. doi: 10.1371/journal.pntd.0001170
5. Jourdan PM, Holmen SD, Gundersen SG, Roald B, Kjetland EF. HIV target cells in Schistosoma haematobium-infected female genital mucosa. Am J Trop Med Hyg (2011) 85(6):1060–4. doi: 10.4269/ajtmh.2011-0135
6. Kleppa E, Ramsuran V, Zulu S, Karlsen GH, Bere A, Passmore JA, et al. Effect of female genital schistosomiasis and anti-schistosomal treatment on monocytes, CD4+ T-cells and CCR5 expression in the female genital tract. PLoS One (2014) 9(6):e98593. doi: 10.1371/journal.pone.0098593
7. Kjetland EF, Poggensee G, Helling-Giese G, Richter J, Sjaastad A, Chitsulo L, et al. Female genital schistosomiasis due to Schistosoma haematobium.
42. Mutengo MM, Mduluza T, Kelly P, Mwansa JCL, Kwenda G, Musonda P, et al. Low IL-6, IL-10, and TNF-alpha and High IL-13 Cytokine Levels Are Associated with Severe Hepatic Fibrosis in Schistosoma mansoni Chronically Exposed Individuals. *J Parasit Res* (2018) 2018:9754060. doi: 10.1155/2018/9754060

43. Pearce EI, MacDonald AS. The immunobiology of schistosomiasis. *Nat Rev Immunol* (2002) 2(7):499–511. doi: 10.1038/nri843

44. Marsden V, Donaghy H, Bertram KM, Harman AN, Nasr N, Keoshkerian E, et al. Herpes simplex virus type 2-infected dendritic cells produce TNF-alpha, which enhances CCR5 expression and stimulates HIV production from adjacent infected cells. *J Immunol* (2015) 194(9):4438–45. doi: 10.4049/jimmunol.1401706

45. Yegorov S, Joag V, Galiwango RM, Good SV, Mpendo J, Tannich E, et al. Schistosoma mansoni treatment reduces HIV entry into cervical CD4+ T cells and induces IFN-I pathways. *Nat Commun* (2019) 10(1):2296. doi: 10.1038/s41467-019-09900-9

46. Dupnik KM, Reust MJ, Vick KM, Yao B, Miyaye D, Lyimo E, et al. Gene Expression Differences in Host Response to Schistosoma haematobium Infection. *Infect Immun* (2019) 87(1):e00291–18. doi: 10.1128/IAI.00291-18

47. Kjetland EF, Ndhllovu PD, Mduluza T, Gomo E, Gwanzura L, Midzi N, et al. Genital schistosomiasis in women: a clinical 12-month in vivo study following treatment with praziquantel. *Trans R Soc Trop Med Hyg* (2006) 100(8):740–52. doi: 10.1016/j.trstmh.2005.09.010

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Sturt, Webb, Patterson, Phiri, Mweene, Kjetland, Mudenda, Mapani, Mutengo, Chipeta, van Dam, Corstjens, Ayles, Hayes, Hansing, Cools, van Lieshout, Helmby, McComsey, Francis and Bustinduy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.